CKCaren M. van Kammen

Caren M. van Kammen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Caren M. van Kammen has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Liposomal encapsulation of L-arginine and L-citrulline enhances pharmacokinetics and therapeutic effects in a model of preeclampsia and fetal growth restriction

    by Caren van Kammen, Myrthe Brink, Magdalena Minnion, Martin Feelisch, Raymond Schiffelers, Titia Lely, Fieke Terstappen

    The online version contains supplementary material available at 10.1038/s41598-026-43958-y.


  • Open Access

    Impaired placental vascular remodeling and persistent uNK cells in the RUPP model: A time-dependent perspective

    by C.M. van Kammen, F.M. Al Darwish, G.J. Strijkers, B.F. Coolen, L.K. Alles, M.M. Faas, R. Schiffelers, A.T. Lely, F. Terstappen


  • Open Access

    Liposomal encapsulation of L-arginine and L-citrulline enhances therapeutic effects in a rat model of Preeclampsia and Fetal Growth Restriction

    by Caren M. van Kammen, Myrthe J. Brink, Magdalena Minnion, Martin Feelisch, Schiffelers Raymond, A. Titia Lely, Fieke Terstappen

    Background: L-arginine and L-citrulline improve vascular health in Preeclampsia (PE) and Fetal growth restriction (FGR). However, the short half-life of these amino acids limits their efficacy. This study investigates pharmacokinetics, delivery, and therapeutic outcomes of liposomal encapsulation of L-arginine and L-citrulline in a rat model of PE and FGR. Method: Firstly, the pharmacokinetics of liposome-encapsulated L-arginine (Encapsulated L-arg) was compared to that of free L-arginine (Free L-arg) in normal pregnant (NP) dams, following single intravenous administration. Secondly, the therapeutic effect on maternal blood pressure and fetal weight were studied in NP rats and the reduced uterine perfusion pressure (RUPP) model for PE and FGR. Treatment groups consisted of Encapsulated L-arginine and L-citrulline (Encapsulated AAs); ratio 1:1, Free L-arginine and L-citrulline (AAs), or PBS, administered intravenously for five consecutive days. Blood and organs were analyzed for amino acid concentrations and fluorescence to assess the biodistribution profile of the liposomes. Nitrite and nitrate were quantified to measure changes in endogenous nitric oxide production in the pharmacokinetic study. Results: Liposomal encapsulation increased the area under the curve of blood arginine concentration-time curves >120-fold. Encapsulated AAs led to a marked increase in plasma and placental tissue concentrations compared to their free forms. Encapsulated AAs reduced maternal blood pressure in RUPP without affecting fetal weight. Enlarged spleens were observed in both Encapsulated AAs groups. Conclusions: The enhanced pharmacokinetics enabled by liposomal encapsulation effectively increased placental delivery of L-arginine and L-citrulline and reduced hypertension. Optimizing composition could enhance efficacy on FGR, making Encapsulated AAs a promising strategy for managing PE and FGR. The etiology of the observed maternal splenomegaly observed warrants further research before this novel approach can be clinically implemented.

  • Open Access

    Targeted lipid nanoparticles to prevent trans-placental passage in the ex vivo human placental cotyledon perfusion model

    by Caren van Kammen, Hedwig van Hove, Dimitrios Kapsokalyvas, Rick Greupink, Raymond Schiffelers, Titia Lely, Fieke Terstappen

    Medication use during pregnancy poses risks to both the mother and the fetus. These risks include an elevated potential for fetotoxicity due to placental drug transport. Nanomedicines offer a promising solution by potentially preventing trans-placental passage. Targeted nanomedicines could enhance safety and efficacy in treating maternal or placental pathophysiology. Our study investigates placental transfer kinetics of targeted lipid nanoparticles (LNPs) in an ex vivo human placenta cotyledon perfusion model. We collected human placentas for dual-side ex vivo placental perfusions. Targeted LNPs with a fluorescence tag were introduced into the maternal circuit of each placenta. To establish if there was trans-placental passage of LNPs to the fetal circuit, we collected samples from maternal and fetal circuits throughout the six hours of the perfusion. We determined the fluorescence signal using a multi-mode microplate reader and Multiphoton microscopy to localize the LNPs in the placenta tissue. Data from perfused placenta tissue showed no significant transfer of the fluorescently labeled LNPs across the placental barrier to the fetal circuit. Localization of targeted LNPs in tissue samples is mainly observed in the maternal blood space of the placenta. Our results suggest that targeted LNPs present a promising strategic approach to prevent trans-placental passage to the fetus. Our future perspectives involve investigating the efficacy of targeted LNPs as well as loading targeted LNPs with nucleic acid-based therapeutics to investigate their therapeutic potential. Graphical Abstract


  • Open Access

    Targeted lipid nanoparticles to prevent trans-placental passage in the ex vivo human placental cotyledon perfusion model

    by Caren van Kammen, Fieke Terstappen, Hedwig van Hove, Dimitrios Kapsokalyvas, Raymond Schiffelers, Rick Greupink, Titia Lely

    Background: Medication use during pregnancy poses risks to both the mother and the fetus. These risks include an elevated potential for fetotoxicity due to placental drug transport. Nanomedicines offer a promising solution by potentially preventing trans-placental passage. Targeted nanomedicines could enhance safety and efficacy in treating maternal or placental pathophysiology. Our study investigates placental transfer kinetics of targeted lipid nanoparticles (LNPs) in an ex vivo human placenta cotyledon perfusion model. Methods: We collected human placentas for dual-side ex vivo placental perfusions. Targeted lipid LNPs with a fluorescence tag were introduced into the maternal circuit of each placenta. To establish if there was trans-placental passage of LNPs to the fetal circuit, we collected samples from maternal and fetal circuits throughout the six hours of the perfusion. We determined the fluorescence signal using a multi-mode microplate reader and Multiphoton microscopy to localize the the LNPs in the placenta tissue. Results: Data from perfused placenta tissue showed no significant transfer of the fluorescently labeled LNPs across the placental barrier to the fetal circuit. Localization of targeted LNP in tissue samples is mainly observed in the maternal blood space of the placenta. Conclusion: Our results suggest that targeted LNPs present a promising strategic approach to prevent trans-placental passage to the fetus. Our future perspectives involve investigating the efficacy of targeted LNPs as well as loading targeted LNPs with nucleic acid-based therapeutics to investigate their therapeutic potential.

  • Open Access

    Reduced uterine perfusion pressure as a model for preeclampsia and fetal growth restriction in murine: a systematic review and meta-analysis

    by Caren M. van Kammen, Seija E. L. Taal, Kimberley E. Wever, Joey P. Granger, A. Titia Lely, Fieke Terstappen

    The reduced uterine perfusion pressure (RUPP) model is frequently used to study preeclampsia and fetal growth restriction. An improved understanding of influential factors might improve reproducibility and reduce animal use considering the variability in RUPP phenotype. We performed a systematic review and meta-analysis by searching Medline and Embase (until 28 March, 2023) for RUPP studies in murine. Primary outcomes included maternal blood pressure (BP) or proteinuria, fetal weight or crown-rump length, fetal reabsorptions, or antiangiogenic factors. We aimed to identify influential factors by meta-regression analysis. We included 155 studies. Our meta-analysis showed that the RUPP procedure results in significantly higher BP (MD = 24.1 mmHg; [22.6; 25.7]; n = 148), proteinuria (SMD = 2.3; [0.9; 3.8]; n = 28), fetal reabsorptions (MD = 50.4%; [45.5; 55.2]; n = 42), circulating soluble FMS-like tyrosine kinase-1 (sFlt-1) (SMD = 2.6; [1.7; 3.4]; n = 34), and lower fetal weight (MD = −0.4 g; [−0.47; −0.34]; n = 113. The heterogeneity (variability between studies) in primary outcomes appeared ≥90%. Our meta-regression identified influential factors in the method and time point of BP measurement, randomization in fetal weight, and type of control group in sFlt-1. The RUPP is a robust model considering the evident differences in maternal and fetal outcomes. The high heterogeneity reflects the observed variability in phenotype. Because of underreporting, we observed reporting bias and a high risk of bias. We recommend standardizing study design by optimal time point and method chosen for readout measures to limit the variability. This contributes to improved reproducibility and thereby eventually improves the translational value of the RUPP model.


  • Open Access

    Assessment of feto-placental oxygenation and perfusion in a rat model of placental insufficiency using T2* mapping and 3D dynamic contrast-enhanced MRI

    by Fatimah M. Al Darwish, Bram F. Coolen, Caren M. van Kammen, Lindy K. Alles, Judith de Vos, Raymond M. Schiffelers, Titia A. Lely, Gustav J. Strijkers, Fieke Terstappen


  • Open Access

    Nanomedicines: An approach to treat placental insufficiency and the current challenges

    by C.M. van Kammen, S.J. van Woudenberg, R. Schiffelers, F. Terstappen, A.T. Lely